Cordlife Group Limited (CLIFF)
USD 0.12
(-8.61%)
USD 0.12
(-8.61%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 55.73 Million SGD | 1.04% |
| 2022 | 55.15 Million USD | 31.33% |
| 2021 | 41.99 Million SGD | -5.9% |
| 2020 | 44.63 Million SGD | -2.54% |
| 2019 | 45.79 Million SGD | -24.09% |
| 2018 | 60.33 Million SGD | -11.68% |
| 2017 | 68.3 Million SGD | 13.92% |
| 2016 | 59.96 Million SGD | 0.56% |
| 2015 | 59.62 Million SGD | 39.43% |
| 2014 | 42.76 Million SGD | -12.88% |
| 2013 | 49.08 Million SGD | 41.45% |
| 2012 | 34.7 Million SGD | 14.62% |
| 2011 | 30.27 Million SGD | 17.93% |
| 2010 | 25.67 Million SGD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 Q4 | 27.6 Million USD | 175.31% |
| 2023 Q1 | 10.63 Million SGD | -63.22% |
| 2023 FY | 55.73 Million SGD | 1.04% |
| 2023 Q2 | 28.31 Million USD | 166.16% |
| 2023 Q3 | 10.02 Million SGD | -64.58% |
| 2022 Q1 | 9.67 Million SGD | -67.02% |
| 2022 Q2 | 26.23 Million USD | 171.06% |
| 2022 Q3 | 10.06 Million SGD | -61.63% |
| 2022 FY | 55.15 Million USD | 31.33% |
| 2022 Q4 | 28.91 Million USD | 187.24% |
| 2021 Q4 | 29.35 Million SGD | 171.58% |
| 2021 Q3 | 10.8 Million SGD | -53.36% |
| 2021 FY | 41.99 Million SGD | -5.9% |
| 2021 Q1 | 10.15 Million SGD | -58.34% |
| 2021 Q2 | 23.17 Million SGD | 128.17% |
| 2020 Q1 | 9.23 Million SGD | -43.66% |
| 2020 Q4 | 24.37 Million SGD | 103.23% |
| 2020 FY | 44.63 Million SGD | -2.54% |
| 2020 Q3 | 11.99 Million SGD | -54.29% |
| 2020 Q2 | 26.24 Million SGD | 184.25% |
| 2019 Q1 | 16.61 Million SGD | 57.57% |
| 2019 FY | 45.79 Million SGD | -24.09% |
| 2019 Q4 | 16.38 Million SGD | 6.24% |
| 2019 Q3 | 15.42 Million SGD | -6.7% |
| 2019 Q2 | 16.53 Million SGD | -0.52% |
| 2018 Q3 | 16.87 Million SGD | -4.28% |
| 2018 Q2 | 17.62 Million SGD | -0.45% |
| 2018 Q4 | 10.54 Million SGD | -37.49% |
| 2018 FY | 60.33 Million SGD | -11.68% |
| 2018 Q1 | 17.7 Million SGD | 8.02% |
| 2017 Q2 | 15.85 Million SGD | 11.47% |
| 2017 Q3 | 16.58 Million SGD | 4.62% |
| 2017 FY | 68.3 Million SGD | 13.92% |
| 2017 Q1 | 14.22 Million SGD | -6.58% |
| 2017 Q4 | 16.39 Million SGD | -1.2% |
| 2016 Q4 | 15.22 Million SGD | 3.92% |
| 2016 Q2 | 15.6 Million SGD | 4.44% |
| 2016 FY | 59.96 Million SGD | 0.56% |
| 2016 Q1 | 14.93 Million SGD | 2.7% |
| 2016 Q3 | 14.65 Million SGD | -6.08% |
| 2015 Q1 | 14.27 Million SGD | 0.1% |
| 2015 Q4 | 14.54 Million SGD | 0.01% |
| 2015 Q3 | 14.54 Million SGD | -7.9% |
| 2015 Q2 | 15.79 Million SGD | 10.62% |
| 2015 FY | 59.62 Million SGD | 39.43% |
| 2014 FY | 42.76 Million SGD | -12.88% |
| 2014 Q4 | 14.26 Million SGD | 7.55% |
| 2014 Q3 | 13.25 Million SGD | -3.99% |
| 2014 Q2 | 13.81 Million SGD | 16.94% |
| 2014 Q1 | 11.8 Million SGD | -2.71% |
| 2013 Q1 | 7.2 Million SGD | -22.05% |
| 2013 FY | 49.08 Million SGD | 41.45% |
| 2013 Q3 | 11.33 Million SGD | 3.55% |
| 2013 Q2 | 10.94 Million SGD | 51.93% |
| 2013 Q4 | 12.13 Million SGD | 7.13% |
| 2012 Q1 | 6.91 Million SGD | -2.67% |
| 2012 FY | 34.7 Million SGD | 14.62% |
| 2012 Q2 | 7.48 Million SGD | 8.17% |
| 2012 Q3 | 8.63 Million SGD | 15.48% |
| 2012 Q4 | 9.23 Million SGD | 6.95% |
| 2011 Q4 | 7.1 Million SGD | -2.28% |
| 2011 Q2 | 7.02 Million SGD | 14.98% |
| 2011 Q1 | 6.1 Million SGD | 0.0% |
| 2011 FY | 30.27 Million SGD | 17.93% |
| 2011 Q3 | 7.27 Million SGD | 3.56% |
| 2010 FY | 25.67 Million SGD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| American Bio Medica Corporation | 913 Thousand USD | -6004.053% |
| Arrayit Corporation | 4.37 Million USD | -1173.159% |
| Atlantic International Corp. | - USD | -Infinity% |
| Biocept, Inc. | 25.85 Million USD | -115.523% |
| Bioqual, Inc. | 58.59 Million USD | 4.883% |
| CardioGenics Holdings Inc | - USD | -Infinity% |
| DermTech, Inc. | 15.29 Million USD | -264.344% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 7.38 Billion USD | 99.245% |
| HTG Molecular Diagnostics, Inc. | 6.36 Million USD | -775.402% |
| iMD Companies, Inc. | - USD | -Infinity% |
| IDenta Corp. | 1.05 Million USD | -5199.594% |
| Interpace Biosciences, Inc. | 40.21 Million USD | -38.584% |
| Integrative Health Technologies, Inc. | 447.49 Thousand USD | -12353.659% |
| InVitro International | 792.62 Thousand USD | -6931.041% |
| Lumos Diagnostics Holdings Limited | 11.13 Million USD | -400.674% |
| Many Bright Ideas Technologies Inc. | - USD | -Infinity% |
| Medical Imaging Corp. | 7.22 Million USD | -671.432% |
| NovelStem International Corp. | 12 Thousand USD | -464316.667% |
| Optigenex Inc. | 465.97 Thousand USD | -11859.997% |
| PharmChem, Inc. | 6.01 Million USD | -826.917% |
| Proteome Sciences plc | 6.4 Million USD | -770.694% |
| Response Genetics, Inc | 18.04 Million USD | -208.925% |
| Rennova Health, Inc. | 13.03 Million USD | -327.503% |
| RushNet, Inc. | 1.78 Million USD | -3017.1% |
| ScreenPro Security Inc. | 1.91 Million USD | -2811.547% |
| Stella Diagnostics Inc. | - USD | -Infinity% |
| StageZero Life Sciences Ltd. | 3.79 Million USD | -1368.482% |
| Todos Medical Ltd. | 7.69 Million USD | -624.237% |